Path Fertility receives $2M SBIR grant from NIH to develop epigenetic diagnostics for male fertility and cancer risk assessment.
Amount Raised
$2 Million
Round Type
Grant
Salt Lake CityBiotechnologyHealth CareGeneticsHealth DiagnosticsInvestors
Description
Path Fertility, a Salt Lake City-based molecular diagnostics company, received a $2M Direct to Phase II Small Business Innovation Research (SBIR) grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The grant will fund development and clinical validation of an epigenetic diagnostic for non-obstructive azoospermia (NOA) and associated cancer risk. Path Fertility's platform includes SpermQT, a clinically validated epigenetic sperm quality test, and NOA Guide, a diagnostic for predicting surgical sperm retrieval.
Who to call at Path Fertility, and when
A new round usually means Path Fertility is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Path Fertility raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Path Fertility, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Path Fertility. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Path Fertility raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Path Fertility raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.